To determine whether live-attenuated feline immunodeficiency virus (FIV) proviral DNA will induce protective immunity, a plasmid clone constructed with a FIV provirus containing a deletion in the viral accessory gene vif (FIV-pPPR-⌬vif) was inoculated as proviral DNA into four cats by the intramuscular route. After 43 weeks, these cats were boosted with the same proviral plasmid. Analysis of peripheral blood mononuclear cells at several time points after the primary and booster inoculations revealed no detectable virus or proviral DNA. At 6 weeks after the booster, immunized cats and additional naive control cats were challenged with a cell-free preparation of the infectious biological isolate FIV-PPR by the intraperitoneal route. Virus was detected after challenge in unvaccinated control cats but not in any of the FIV-pPPR-⌬vif-immunized cats. Both FIV Gag-and Env-specific cytotoxic T lymphocyte (CTL) activities were detected in peripheral blood cells of control cats after challenge infection, whereas only one of four cats immunized with FIV-pPPR-⌬vif DNA exhibited a measurable CTL response to Env following challenge. Although anti-Gag antibodies were not detected after both proviral DNA inoculation and challenge, anti-Env antibodies were found in FIV-pPPR-⌬vif-immunized cats after vaccination as well as after challenge. These findings indicate that inoculation with FIV-pPPR-⌬vif proviral DNA induced resistance to challenge with infectious FIV and that a vif deletion mutant may provide a relatively safe attenuated lentiviral vaccine.
INTRODUCTION
Feline immunodeficiency virus (FIV) is a lentivirus that causes progressive immunodeficiency syndrome in cats that is characterized by CD4 T cell depletion. Thus, this animal model is valuable for investigating human immunodeficiency virus (HIV) infection in humans (Pedersen et al., 1987; Siebelink et al., 1990; Willett et al., 1991) . Advantages of the FIV animal model include a genome organization and cell tropism similar to that of HIV and a clinical course and disease pathogenesis similar to that of AIDS in humans (Beebe et al., 1994; Brown et al., 1991; Dean et al., 1996; Diehl et al., 1995; English et al., 1993; Talbott et al., 1989; Willet et al., 1997; Woo et al., 1997; Yamamoto et al., 1988) . In addition, the FIV model system provides a practical, economical, and safe alternative to the use of non-human primates in HIV research and the development of vaccines and therapies against AIDS.
Much of the work using the FIV model for vaccine development has focused on immunization with whole inactivated-virus-or fixed-virus-infected cells. The first effective FIV vaccine of this type used killed FIV-Petaluma-infected cells or inactivated whole FIV-Petaluma virus and was shown to protect against challenge with low-dose homologous and some heterologous FIV isolates (Yamamoto et al., 1991 (Yamamoto et al., , 1993 . However, subsequent studies have revealed that these vaccines cannot protect against challenge with antigenically distinct FIV isolates (Bishop et al., 1996; Hosie et al., 1995; Johnson et al., 1994) . In addition, one study using the fixed FIV-Petaluma-infected cell vaccine reported a breakthrough in vaccine protection against homologous challenge when animals were monitored up to 50 weeks postchallenge (pc) (Bishop et al., 1996) , and a second study using a similar fixed FIV-infected cell vaccine reported no protection from cell-free challenge at 1 year postvaccination (Matteucci et al., 1997) . These results suggest that sterilizing immunity is not achieved and persistent latent challenge virus infections can occur despite vaccination with the inactivated FIV vaccines.
The most successful vaccines to date in the simian immunodeficiency virus (SIV) model have been live, attenuated viruses with deletions in viral accessory genes (Almond et al., 1995; Daniel et al., 1991; Wyand et al., 1996) . Inoculation of adult and juvenile macaques with a nef deletion mutant of SIV did not cause disease but produced a persistent low-level infection and generated anti-SIV antibodies. These immunized animals were protected from challenge with high doses of cell-free pathogenic virus more than 2 years postvaccination (Almond et al., 1995) . However subsequent studies have reported induction of AIDS after inoculation with an attenuated SIV mutant with multiple deletions, including nef and vpr, in neonatal macaques and in adult macaques after prolonged follow-up studies (Baba et al., 1995 (Baba et al., , 1999 . Therefore the attenuation and impairment of replication induced by deletion of these genes was insufficient to produce a safe nonpathogenic virus vaccine.
Inoculation of plasmid DNA transient expression vectors directly into muscle tissue has been found to induce long-lasting humoral and cellular immune responses to a variety of pathogens, including influenza B virus, hepatitis B virus, and SIV; additionally, protection from challenge with heterologous antigens has been reported (Chattergoon et al., 1997; Robinson et al., 1999) . Several reports demonstrated that inoculation of cloned proviral DNA into animals resulted in virus expression and infection (Letvin et al., 1991; Portis et al., 1992; Rigby et al., 1997; Sparger et al., 1997; Willems et al., 1992) . The advantages of DNA immunization over live-virus or inactivated-virus preparations include the relative stability of DNA and ease of purification. Thus, it is feasible to produce large quantities of attenuated forms of virus as plasmids containing proviral DNA in contrast to infectious virus grown in cell cultures. Furthermore, problems associated with inactivation steps and sequence changes resulting from passage of virus in cell culture are not encountered when propagating and purifying cloned viral DNA plasmids.
In this study, we used injection of infectious proviral DNA as a mode for delivery of a vif deletion mutant of FIV. We previously reported that inoculation of cats with wildtype (WT) FIV-pPPR proviral DNA produced an infection detectable by both antiviral antibody and virus isolation from peripheral blood mononuclear cells (PBMC) and viremia kinetics similar to that of inoculation with live virus preparations (Sparger et al., 1997) . The FIV-pPPR⌬vif proviral construct encodes a 375-bp deletion within the vif (viral infectivity factor) gene and exhibits very low levels of virus replication compared to the WT FIV-pPPR in feline peripheral blood mononuclear cells (PBMC) and monocyte-derived macrophages in vitro (Lockridge et al., 1999) , both target cell types for FIV infection in vivo (Beebe et al., 1994; Dean et al., 1996 Dean et al., , 1999 Dow et al., 1999; English et al., 1993) . Lentivirusencoded Vif functions at a late stage of the virus cycle and is critical for viral cell-free infectivity in vitro and in vivo (Borman et al., 1995; Bouyac et al., 1997; Desrosiers et al., 1998; Fouchier et al., 1996; Gabuzda et al., 1994; Harmache et al., 1996; Inoshima et al., 1996; Sakai et al., 1993; Shacklett and Luciw, 1994; Simon and Malim, 1996; Tomonaga et al., 1992; vonSchwedler et al., 1993) . Here we demonstrate that inoculation of cats with FIV-pPPR⌬vif proviral DNA protected cats against challenge with the homologous FIV-PPR biological isolate. This DNA vaccine induced low levels of anti-Env antibodies. Protection was achieved without detectable viremia.
RESULTS AND DISCUSSION

Proviral DNA immunization and anti-viral immune responses
Presence of the vif gene in genomes of all known lentiviruses, except equine infectious anemia virus (EIAV), suggests a critical role for this gene in lentiviral infection and viral replication. Indeed, inoculation of hosts with vif-deletion mutants of caprine arthritis encephalitis virus (CAEV), SIV, and FIV have all resulted in very low viral loads and minimal production of antiviral antibodies (Desrosiers et al., 1998; Harmache et al., 1996; Inoshima et al., 1996) . In a previous report, we described the vif-deletion mutant FIV-pPPR⌬vif derived from WT infectious molecular clone FIV-pPPR (Phillips et al., 1990; Sparger et al., 1994) and reported that replication of this mutant was severely restricted in cell-culture systems of feline PBMC and monocyte-derived macrophages (Lockridge et al., 1999) . To determine the in vivo infectivity of FIV vif-mutant proviral DNA, we inoculated cats with FIV-pPPR⌬vif proviral DNA and compared infection kinetics to those of cats inoculated with either WT FIV-pPPR or a biological FIV-Petaluma PBMC virus stock. Specific pathogen free (SPF) cats were inoculated intramuscularly (im) with 600 g of either FIV-pPPR⌬vif plasmid DNA (n ϭ 4) or FIV-pPPR plasmid DNA (n ϭ 2) or intraperitoneally (ip) with 10 3 TCID 50 of a FIV-Petaluma PBMC virus stock (n ϭ 2) (Table 1) . Two negative control cats were inoculated ip with uninfected tissue culture media. All of the FIV-pPPR⌬vif-inoculated cats (Nos. 073, 154, 212, and 213 ) and one of the WT pPPRinoculated cats (No. 190) displayed a transient fever starting 3 h post inoculation (pi) that was resolved within 24 h, presumably due to residual endotoxin remaining in the plasmid DNA preparation. No other adverse side effects were observed in cats as a result of im injection of plasmid proviral DNA.
All cats receiving DNA inoculations remained clinically healthy and did not exhibit lymphadenopathy or notable changes in leukocyte or neutrophil counts compared to the SPF control cats at any time following inoculation (data not shown). Lymphadenopathy and decreased CD4:CD8 T cell ratios were observed in both of the FIV-Petaluma PBMC -inoculated cats by 11 weeks pi as has been previously described for this pathogenic FIV isolate (Barlough et al., 1991 (Barlough et al., , 1993 . However, neither WT FIV-pPPR-or FIV-pPPR⌬vif-inoculated cats exhibited a significant decrease in CD4:CD8 T cell ratios when com-pared to age-matched, SPF control cats (data not shown). Absence of CD4 T cell alterations has been previously reported for the relatively nonpathogenic molecular clone FIV-pPPR (Dean et al., 1999; Sparger et al., 1994) .
We previously demonstrated that all cats inoculated im with 100-300 g of WT FIV-pPPR proviral DNA were virus isolation positive by 10 weeks pi (Sparger et al., 1997) . Cats within the current study, inoculated im with 600 g of FIV-pPPR⌬vif proviral DNA, remained virus negative as determined by semi-quantitative virus isolation from peripheral blood at various time points Յ43 weeks pi (Table  2) . Virus was detected in both cats inoculated with FIV-Petaluma PBMC virus and in one of two cats inoculated with FIV-pPPR plasmid DNA (No. 150) by 4 weeks pi. However, virus was not isolated from the second FIV-pPPRinoculated cat (No. 190 ) and the four FIV-pPPR⌬vif-inoculated cats or from the SPF negative control cats, for Յ43 weeks pi. These results are consistent with those from previous in vivo lentiviral vif-mutant inoculations in which inoculation of either FIV⌬vif virus in cats or SIV⌬vif virus in monkeys did not induce viremia detectable by virus isolation from PBMC (Desrosiers et al., 1998; Inoshima et al., 1996) . Also similar to the SIV⌬vif virus inoculation study, proviral DNA was not amplified by PCR from PBMC sampled at 8, 16, and 43 weeks after inoculation or from popliteal lymph nodes harvested at 9 and 12 weeks pi (Table 3) .
Cats were monitored for seroconversion by an ELISA that measures anti-FIV p24-Gag. Antibody responses against FIV p24-Gag were detected by 8 weeks pi in both FIV-Petaluma PBMC virus-inoculated and FIV-pPPR-inoculated cats and were sustained throughout the initial phase of this study (Table 4 ). However, none of the FIV-pPPR⌬vif-inoculated cats demonstrated detectable antiviral antibody responses during the 43 weeks pi when tested with a recombinant FIV p24 ELISA, with a commercial FIV ELISA assay, or by Western blot. The absence of detectable viremia and anti-p24-Gag antibody in FIV-pPPR⌬vif-inoculated cats suggests that FIV-pPPR⌬vif replication was severely restricted or absent in vivo. It is more likely that viral replication did occur but in amounts below the detection limits of our assays or replication may have occurred in cell subsets sequestered in tissues not tested by virus isolation.
Absence of detectable anti-p24-Gag antibody, when assayed by standard serological assays, was previously reported for monkeys inoculated with a SIV⌬vif virus (Desrosiers et al., 1998) and in cats inoculated with plasmid DNA containing a FIV provirus with an in-frame deletion in pol (Hosie et al., 1998) . However, an ultrasensitive ELISA was capable of measuring anti-SIV antibodies in all the SIV⌬vif-inoculated monkeys, and these weak antibody responses persisted for more than a year. To this end, a commercially available FIV ELISA assay, as well as Western blot analysis, were used to re-test sera from FIV-pPPR⌬vif-inoculated cats and were unable to detect antiviral antibodies in these cats. To extend the 
a Cats infected with FIV-pPPR and FIV-Petaluma were euthanized (E) 21 weeks after first inoculation. b ND designates not done. 
FIV-pPPR WT Ϫ 10 4 10 6 10 5 analysis of this phenomenon, an FIV concanavalin A (ConA) ELISA was used to detect antibody specific for native FIV envelope proteins in cats inoculated with FIV-pPPR⌬vif. Although none of the inoculated cats was positive for anti-FIV Env antibody at 2 weeks after proviral DNA inoculation ( Fig. 1A) , interestingly, all four FIV-pPPR⌬vif-inoculated cats, as well as cats inoculated with WT FIV-pPPR proviral DNA, were positive for anti-Env antibody by 12 weeks pi with proviral DNA (Fig. 1B) . Although Env-specific antibody endpoint titers measured for the four FIV-pPPR⌬vif-inoculated cats were lower (four-to eightfold) than the positive control serum, their titers were comparable to or greater than those found for the WT FIV-pPPR-inoculated cats (data not shown). The presence of anti-Env antibody in the pPPR⌬vif-inoculated cats is indicative of expression of the vif-deleted provirus post inoculation and suggests possible replication of the virus.
FIV infection is associated with induction of FIV-specific effector and memory cytotoxic T-lymphocyte (CTL) populations Flynn et al., 1996; Hosie and Flynn, 1996; Song et al., 1992; Tellier et al., 1997) . To determine whether FIV-pPPR⌬vif proviral DNA inoculation elicited a cellular immune response in cats, FIVspecific lymphocytotoxicity in precursor CTLs was assayed in PBMC harvested 21 weeks pi and stimulated in vitro with fixed autologous stimulator cells infected with recombinant vaccinia viruses expressing either FIV gag or env gene product. Despite the inability to detect anti-p24-Gag antibody responses, low but significant FIV Gag-or Env-specific memory CTL activity was observed in two of the four FIV-pPPR⌬vif-inoculated cats. One FIV-pPPR⌬vif-inoculated cat (No. 213) and one FIV-Petaluma PBMC virus-inoculated cat (No. 191) exhibited anti-FIV Gag CTL responses, whereas both uninfected control cats were negative for anti-FIV Gag responses (Fig. 2 ). In addition, Env-specific CTL activity was detected in one FIV-pPPR⌬vif-inoculated cat (No. 073) and one FIV-Petaluma PBMC virus-inoculated cat (No. 191) but not in either uninfected control cat. These results indicated that virus replication sufficient to induce CTL responses comparable to those observed in cats inoculated with FIV-Petaluma PBMC , occurred in at least two of the cats inoculated with FIV-pPPR⌬vif. However, CTL responses were measurable in both cats inoculated with the more pathogenic FIV-Petaluma PBMC . It must be considered that additional CTL responses might have been found in the remaining cats if earlier time points pi had been tested. The use of a vaccina virus construct expressing a heterologous FIV env (FIV-Petaluma Env), although of the same clade (A), 
Serum antibody titer to FIV p24 Gag expressed as the reciprocal of the highest dilution positive for antibody. Sera with titers less than 1:100 are antibody negative.
b Cats infected with FIV-pPPR WT and FIV-Petaluma were euthanized (E) 21 weeks pi. may also have decreased the sensitivity of this CTL assay for detection of FIV-pPPR Env-specific activity.
Challenge with infectious FIV
At 43 weeks pi, cats in the FIV-pPPR⌬vif-inoculated group received a booster inoculation of 300 g plasmid FIV-pPPR⌬vif DNA. Adverse side effects were not observed in any cat receiving a booster inoculation of proviral DNA. Semi-quantitative virus isolation was performed on PBMC isolated from the FIV-pPPR⌬vif-inoculated cats on the day of boost (Table 2 ) and 6 weeks postboost (Table 5) . At 49 weeks after inoculation (6 weeks postboost), FIV-pPPR⌬vif-inoculated cats and two SPF cats were challenged ip with 50 TCID 50 of uncloned FIV-PPR virus. Two additional SPF cats were inoculated ip with uninfected tissue culture media. Cats were monitored for clinical signs of acute FIV infection, viremia and anti-FIV antibody and CTL activity for Յ47 weeks postchallenge (pc). Three weeks pc, one FIV-pPPR⌬vif-inoculated cat (No. 073) was euthanized due to a progressive nonregenerative anemia and neutropenia. Findings from histopathologic examination of lymphoid tissues harvested from this cat were not supportive of FIV-associ-ated disease and did not suggest an etiology for the cause of the hematological abnormalities. Although proviral DNA representative of challenge virus based on the presence of wild-type vif sequences was detected in both mesenteric lymph nodes and PBMC harvested from the cat during post mortem examination, the cat was virus isolation negative up until and including the time of death. The remaining three cats inoculated with FIV-pPPR⌬vif exhibited no clinical signs of acute FIV infection and remained clinically healthy throughout the 47 weeks following challenge. Significant decreases in CD4:CD8 T cell ratios was not observed in either FIV-pPPR⌬vif-immunized or unvaccinated control cats challenged with FIV-PPR virus when compared to agematched SPF control cats (data not shown). The lack of CD4:CD8 T cell ratio alterations observed in the unvaccinated control cats is consistent with previous observations where decreased CD4 T cell concentrations were associated only with a later stage of infection with the FIV-PPR biological isolate (Sparger et al., 1994) .
Both challenge control cats became viremic by PBMC virus isolation at 4 weeks pc (Table 5 ). Remarkably, virus could not be isolated from any cat in the FIV-pPPR⌬vif- inoculated group throughout the 47 weeks following challenge. SPF control cats also remained virus negative throughout the study. Virus isolations performed on lymphocytes harvested from auricular lymph nodes sampled at 12 weeks pc were also negative for all FIV-pPPR⌬vifinoculated cats and the SPF control cats, whereas virus was isolated from lymph nodes harvested from both challenge control cats (Table 5 ). Viral DNA was not detected by PCR in PBMC collected at 2, 4, 12, 20, and 47 weeks pc or in peripheral lymph nodes harvested at 12 weeks pc in the three surviving FIV-pPPR⌬vif-immunized cats (Table 6 ). In contrast, viral DNA was amplified from PBMC sampled from unimmunized control cats between 4 and 12 weeks pc and from auricular lymph nodes taken at 12 weeks pc (Table 6 ). These observations are relevant because previous vaccine studies have shown that challenge virus may be detectable in lymphoid tissues, although PBMC remain virus isolation negative following challenge with FIV (Bishop et al., 1996; Hosie and Flynn, 1996) .
All cats were monitored for FIV seroconversion following virus challenge by FIV p24-Gag antibody ELISA. Anti-p24-Gag antibody was detected in the sera of both challenge control cats by 8 weeks pc, whereas anti-p24-Gag antibody was absent in the SPF control cats for the 47 weeks following challenge (Table 7) . Importantly, anti-p24 antibody was never detected in any FIV-pPPR⌬vifinoculated cats throughout the challenge phase of this study, and these results were confirmed by commercial ELISA and Western blot. Taken together, the lack of detectable viremia and absence of anti-p24 Gag antibody in the FIV-pPPR⌬vif-inoculated cats indicate that replication of challenge virus was severely restricted in these cats and suggest that these cats were resistant to infection with WT homologous uncloned FIV-PPR.
Anti-Env antibody was detected in FIV-pPPR⌬vif-inoculated cats at 4 and 12 weeks pc (Figs. 1C and 1D) , and endpoint titers were comparable to those observed in the unvaccinated challenge control cats (Nos. 153 and 211) (data not shown). Because sera were not available from FIV-pPPR⌬vif-inoculated cats on the day of challenge (6 weeks postboost), a distinction between the antiviral responses derived from proviral DNA boost inoculation and biological FIV-PPR challenge is not possible. However, detection of anti-Env antibody following FIG. 2. Detection of FIV Gag-and Env-specific CTL following inoculation. Virus-specific CTL responses were measured in restimulated lymphocytes isolated from peripheral blood obtained at 21 weeks following inoculation. Autologous skin fibroblasts infected with recombinant vaccinia virus expressing either FIV Gag (solid bars) or FIV Env (striped bars) or with wild-type virus (dotted bars) were used in this assay. The release of LDH into the culture supernatant was measured after 4 h using a nonradioactive assay to assay-specific lysis. Results shown are mean values for triplicate cultures at an effector to target cell ratio of 25 to 1, with the exception of Cat 190 for which values shown were measured at an E:T ratio of 10:1 due to an insufficient number of effector cells for testing at multiple E:T ratios. In general, specific lysis increased as E:T ratios increased from 3:1 up to 25:1. Due to higher background LDH release observed with larger numbers of effector cells, (PBMC), values for specific lysis at E:T ratios of 50:1 and higher were not significant. 
Unimmunized Ϫ Ϫ 10 4 10 4 10 6 10 5 10 3 10 5 10 4 ϩ 211
Unimmunized Ϫ Ϫ 10 3 10 3 10 6 10 3 10 5 10 5 10 5 ϩ 257 SPF Control
a PBMC or lymph node lymphocytes cultures negative for FIV p24 are shown as Ϫ; numbers represent lowest concentration of cells from which virus could be isolated by day 42 in culture. A single concentration of lymph node cells (10 6 ) was tested by virus isolation.
b Cat was euthanized (E) 3 weeks pc and was virus isolation negative at time of death. initial proviral DNA inoculation and after proviral DNA boost and challenge provides evidence for induction of virus-specific humoral responses by inoculation with FIV-pPPR⌬vif proviral DNA. These observations indicate that this ConA ELISA previously adapted for detection and characterization of HIV and SIV envelope-specific antibodies (Cole et al., 1997; Robinson et al., 1990) will also provide a sensitive assay for characterizing antibodies to native FIV envelope proteins in future FIV vaccine studies. Active cellular immune responses, including cytolytic T cells have been shown to correlate with control of HIV infection and hypothesized to be major components of protective immunity induced by nef-deleted attenuated SIV isolates (Borrow et al., 1994; Gallimore et al., 1996; Gauduin et al., 1998; Mazzoli et al., 1997; Reimann et al., 1994; Rosenberg et al., 1997; Schmitz et al., 1999; Yang et al., 1997; Yasutomi et al., 1993) . Env-specific effector CTL in peripheral blood and Env-specific memory CTL in lymphoid tissues were also reported to correlate with protective immunity in cats immunized with a whole, inactivated virus vaccine Hosie and Flynn, 1996) . To assess cellular immune responses as possible correlates of protection in our study, FIV Gagand Env-specific memory CTL activity was measured for in vitro stimulated PBMC isolated at 9, 14, and 17 weeks following challenge. Both challenge control cats exhibited elevated FIV Gag-specific activity 9 weeks following challenge (Fig. 3A) . This anti-Gag CTL activity returned to baseline levels by 14 and 17 weeks pc. No significant increase (10% specific lysis) in anti-Gag CTL activity was observed for any of the FIV-pPPR⌬vif-inoculated cats following challenge.
In addition to Gag-specific activity, a marked FIV Env-specific CTL response was observed in challenge control cats (Fig. 3B ). Both challenge control cats demonstrated heightened anti-Env CTL activity at 9 and 14 weeks but not at 17 weeks following challenge. In contrast, only one FIV-pPPR⌬vif-inoculated cat (No. 213) exhibited significant anti-Env CTL activity at 9, 14, and 17 weeks pc. This Env-specific response was comparable to that observed for the challenge control 
Cat was euthanized (E) 3 weeks pc and was virus isolation negative at time of death. 
Unimmunized ND Ϫ Ϫ 10 2 10 3 10 4 10 3 10 3 10 3 211
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This time point represents challenge with 50 TCID 50 of biological FIV-PPR virus and is 5 weeks post booster inoculation with FIV-pPPR⌬vif proviral DNA.
b Serum antibody titer to FIV p24 Gag is expressed as the reciprocal of the highest dilution positive for antibody. c Cat was euthanized (E) 3 weeks pc and was viral antibody negative at time of death.
cats and was greatest at 9 weeks pc, then fell to a small, but significant, level by 17 weeks. Neither of the remaining two FIV-pPPR⌬vif-inoculated cats (Nos. 154 and 212) exhibited a significant increase in anti-Env CTL activity at these time points. These observations do not provide support for peripheral blood CTL activity as the predominant immune response responsible for the protective immunity observed in the FIV-pPPR⌬vif-vaccinated cats. These findings are similar to those of two different studies that revealed no correlation between antiviral CTL activity and induction of protective immune responses in cats vaccinated with a defective provirus encoding a deletion in reverse transcriptase (FIV⌬RT) and a DNA expression construct encoding the feline gamma interferon gene (Flynn et al., 2000; Hosie et al., 1998) . However, analysis of memory CTL populations at earlier time points after vaccination and boost and in lymphoid tissues of FIV-pPPR⌬vif-vaccinated cats will be required to further characterize CTL activity as a component of the anti-FIV immune responses that allowed resistance to viral challenge. Other cellular immune responses facilitating resistance to infection with challenge virus may include CD8 T lymphocyte-derived antiviral factors, which have not yet been well characterized for FIV infection (Bucci et al., 1998; Jeng et al., 1996; Shimojima et al., 1998) .
Summary
We demonstrated that im injection of cats with FIV-pPPR⌬vif proviral DNA did not produce an infection detectable by virus isolation or induction of anti-FIV Gag antibody for Յ49 weeks following inoculation. However, cats inoculated with FIV-pPPR⌬vif proviral DNA were resistant to challenge with homologous, wild-type FIV. This observation contrasts with findings of a different study where goats vaccinated with a vif deletion mutant of caprine arthritis encephalitis virus (CAEV) by proviral DNA inoculation were not protected against WT CAEV challenge (Harmache et al., 1996) and studies with SIV nef deletion mutants that suggest that a detectable ongoing low-level replication of the attenuated virus is needed for maintenance of protective immune responses (Wyand et al., 1996) . However, another study revealed protective immune responses in African green monkeys inoculated with a nef deletion mutant of SIVagm (SIVagm3nef) in the absence of detectable replication of the immunizing virus (Beer et al., 1997) . Assessment for antibody and FIV-specific CTL responses did not reveal obvious immunological mechanisms for protection in these FIV-pPPR⌬vif-inoculated cats. We speculate that FIV-pPPR⌬vif proviral DNA vaccination was successful at inducing protective immunity because of a combined effect of direct expression of viral antigens from the injected proviral DNA and a low-level of replication of attenuated virus produced by this DNA. Issues that need to be addressed are the time points following DNA inoculation at which resistance to challenge virus was effectively induced and the need for a second proviral DNA inoculation (boost). Assessment for virus/proviral DNA in multiple lymphoid tissues harvested from FIV-pPPR⌬vif-inoculated cats at multiple time points will also be necessary to determine whether attenuated virus is sequestered in such tissues. This study indicates that a FIV vif deletion mutant, delivered by proviral DNA injection, may provide an extremely attenuated virus vaccine that is relatively safe from reversion, yet capable of inducing protective immunity without eliciting antibody responses that interfere with viral diagnostic assays. Additional studies focusing on the virus neutralizing activity and avidity of the low titer anti-FIV Env antibody observed in the FIV-pPPR⌬vifvaccinated cats, as well as CTL activity and viral suppressor factors, will be necessary to elucidate mechanisms by which inoculation of FIV-pPPR⌬vif induces resistance to infection with WT homologous FIV.
FIG. 3. Detection of FIV Gag-and Env-specific CTL following challenge. The FIV-specific CTL activity was assayed in restimulated lymphocytes isolated from peripheral blood obtained following challenge with 50 TCID 50 of FIV-PPR virus. The FIV Gag-specific (A) and Envspecific (B) CTL activities were measured at 9, 14, and 17 weeks following challenge. Assay was performed as described in the legend for Fig. 1 . Results shown are mean values for triplicate cultures at an effector to target cell ratio of 12.5 to 1, with the wild-type virus-infected target cell values subtracted. No significant lysis was observed when heterologous targets were used.
MATERIALS AND METHODS
Construction of mutants
The infectious molecular clone WT FIV-pPPR, derived from the FIV-PPR isolate and kindly provided by J. E. Elder, served as the parental construct (Phillips et al., 1990) . Vif-deletion mutant FIV-pPPR⌬vif was created by introducing a 375-bp (bp 5330-5704) deletion within the vif gene of the WT FIV-pPPR clone, as previously described (Lockridge et al., 1999) . Plasmid DNA stocks were prepared by centrifugation to equilibrium twice in cesium chloride-ethidium bromide gradients (Sambrook et al., 1989) and were not assayed for endotoxin concentration. Plasmid DNA stocks used for the boost inoculation at 43 weeks pi were further purified using Endofree Columns (Qiagen Corp.) and endotoxin was undetectable in these plasmid DNA preparation when assayed by a commercial kit (E-Toxate, Sigma Chemical Co.).
Virus stocks
The FIV-Petaluma PBMC virus stock was generated by short-term (Ͻ2 weeks) passage of the biological FIV Petaluma isolate in feline PBMC cultured in complete RPMI media supplemented with recombinant human interleukin-2 (IL-2; 100 U/ml), 10% heat inactivated fetal bovine serum (FBS), L-glutamine, and penicillin-streptomycin. The biological FIV-PPR virus stock used for challenge was derived from a virus preparation chronically passaged on feline PBMC.
Animals and inoculations
Twelve juvenile, SPF cats, aged 4-5 months, were obtained from the SPF cat colony of Dr. J. G. Morris and Dr. Q. R. Rogers (University of California, Davis) and housed in pathogen-free quarters of Animal Resources Services (University of California, Davis). Cats were inoculated by im injection with 600 g of either FIV-pPPR⌬vif plasmid DNA (n ϭ 4) or WT FIV-pPPR plasmid DNA (n ϭ 2) or were inoculated ip with 10 3 TCID 50 of biological FIV-Petaluma PBMC virus stock (n ϭ 2) ( Table 1) . Two negative control cats were inoculated ip with uninfected tissue culture media only. Plasmid DNA was resuspended in 1 ml of sterile physiological saline for inoculation by hypodermic syringe (22 gauge) in the rear limb quadriceps muscle. Animals were assessed daily by physical examination and monitored for clinical signs. Blood samples were obtained every two to four weeks for hematological, virological, and immunological assays. Popliteal lymph nodes were sampled at 9 and 12 weeks postinoculation. Cats in the WT FIV-pPPR-and FIV-Petaluma PBMC -inoculated groups were sacrificed at 21 weeks pi. At 43 weeks pi, all cats in the FIV-pPPR⌬vifinoculated group received a booster inoculation im with 300 g FIV-pPPR⌬vif plasmid DNA.
Challenge
At 49 weeks pi (6 weeks postboost), FIV-pPPR⌬vifinoculated cats and two SPF cats were challenged ip with 50 TCID 50 of an uncloned, biological FIV-pPPR virus stock. Two negative control cats were inoculated ip with uninfected tissue culture media only. At 3 weeks pc (52 weeks pi), one cat from the FIV-pPPR⌬vif group was euthanized due to a progressive nonregenerative anemia. However, viremia was not detected in this cat at the time of death. Blood samples were collected at similar time points as described for DNA inoculation and auricular lymph nodes were sampled at 12 weeks post challenge.
Virus isolation
Semi-quantitative virus isolations were performed on PBMC isolated from peripheral blood by density gradient centrifugation in Ficoll/Hypaque (Histopaque; Sigma). Tenfold serial dilutions of 10 6 PBMC were cocultured with SPF feline PBMC in 24-well plates. Culture supernatants were collected every 3-5 days and virus production was measured by p24 antigen-capture ELISA (Dandekar et al., 1992) for Յ32 days as previously described (Sparger et al., 1997) . Single-cell suspensions of mononuclear cells were prepared by gentle manual homogenization of auricular lymph node biopsies. For lymph node-derived mononuclear cells, 10 6 cells were cultured undiluted in 24-well plates for 28 days and assayed for virus by p24 antigen ELISA as described above.
Hematology and lymphocyte subset analysis
Complete blood cell counts and differential leukocyte counts were performed on peripheral blood samples using standard methods as previously described (Barlough et al., 1991) . Enumeration of CD4 and CD8 peripheral blood lymphocyte subsets and CD4:CD8 ratios were performed by flow cytometric analysis also as previously described (Barlough et al., 1991) .
Anti-FIV Gag antibody detection
Circulating antibodies to FIV p24-Gag in sera following inoculation and challenge were detected by ELISA with recombinant p24 as the solid-phase antigen as previously described (George et al., 1993) . A commercially available anti-FIV antibody ELISA detection kit (IDEXX), as well as Western blot, were used to confirm results from the recombinant p24 ELISA.
Detection of proviral DNA by PCR
Genomic DNA was extracted from PBMC and peripheral lymph nodes using a commercial kit (QIAamp Tissue Kit, Qiagen Corp.) and was assayed for FIV proviral DNA by nested PCR using conditions previously described (Dean et al., 1999) . Round-one primers used were as follows: GAG 1: GGGAATGGACAGGGGCGAGAT (forward) and GAG 2: TTGCTGCACTTGATTCACTGG (reverse). Second-round primers were GAG3: TTGAC-CCAAAAATGGTGTCCA (forward) and GAG5: GCTGGTG-CAAATCTTGCTTC (reverse) and yielded a 312-bp product. Each sample was tested three times or more by PCR amplification before a final result was recorded. Nested PCR using these Gag primers detected Ͻ20 proviral copies per microgram of genomic DNA.
Detection of FIV Env antibody by ELISA
Serum samples from inoculated cats were analyzed for their reactivity to native viral envelope proteins in a ConA ELISA. This assay maximizes the maintenance of protein structure and has been adapted from assays previously described for HIV-1 (Robinson et al., 1990) and modified for SIV (Cole et al., 1997) . Briefly Immulon 2HB plates (Dynatech Laboratories) were incubated with 5.0 g ConA (Vector Laboratories) per well in 100 l of phosphate-buffered saline (PBS) for 1 h at room temperature and then washed two times with PBS/0.05% Tween-20. ConA plates were then used to adsorb envelope glycoproteins from Triton X-100-disrupted, gradient purified preparations of biological FIV-PPR (1 g of total protein, as determined by Biorad DC Protein assay, per 50 l in each well) for 2 h at room temperature. ConAadsorbed wells were next washed five times with PBS/ 0.05% Tween-20 and blocked with 100 l per well of BLOTTO (5% nonfat dry milk in PBS/0.05% Tween-20) per well overnight at 4°C. After blocking solution was removed, 50 l of serial dilutions (1:50-51,200 in blotto) of each serum sample were added to each well and incubated for 1 h at room temperature. Sample wells were again washed five times with PBS/0.05% Tween-20 before incubating 50 l of peroxidase-conjugated anti-cat IgG (Kirkgaard and Perry Laboratories) per well for a 1-h incubation at room temperature. Wells were once again washed five times with PBS/0.05% Tween-20, and 200 l of TM-Blue (Intergen) substrate was added and left for 20 min while shaking at room temperature. Color development was determined by the addition of 50 l of 1 N sulfuric acid per well. Antibody reactivity to ConA-adsorbed glycoprotein substrates was then determined by measuring optical density (O.D.) at 450 nm, using an automated plate reader (Dynatech).
Cytotoxic T-lymphocyte assay
Virus-specific CTL activity was measured in PBMC of vaccinated and control cats at various time points after inoculation and challenge, using a method previously described , with the following modifications. Target cells were autologous skin fibroblasts collected by skin biopsy prior to inoculation and stored at third passage at Ϫ70°C. Stimulator cells were prepared from autologous PBMC collected both prior to and following inoculation and cultured in complete RPMI media supplemented with 7.5 g/ml ConA (Sigma), IL-2 (100 U/ml), 10% heat inactivated FBS, L-glutamine, and penicillin-streptomycin, for 48 h at 37°C. Lymphoblasts were infected with 10 PFU/cell of recombinant vaccinia virus expressing either FIV-Gag (vFIV-GL14-gag, provided by J. Flynn, Glasgow, Scotland) or FIV-Env (vFIV-PET-env, provided by E. B. Stephens, Gainesville, FL) proteins in complete RPMI for 1 h. Cells were washed and resuspended in complete RPMI with 2% FBS for 3 h at 37°C to allow optimal expression of the FIV proteins, then fixed overnight in 0.1% paraformaldehyde in PBS at 4°C. Cells were washed before storage at 2 ϫ 10 6 cells/ml in PBS at 4°C. PBMC serving as effector cells were restimulated in vitro by addition of fixed antigen-presenting vFIV/GL14-gag or vFIV/PET-env stimulator cells at a stimulator to responder ratio of 1:10 to 1:20. Effectors were cultured for 5-7 days with stimulator cells in complete RPMI media, then an additional 5-7 days in complete RPMI media containing 200 U/ml IL-2.
The day before the CTL assay, 1 ϫ 10 4 target cells per well in DMEM/L-15 media supplemented with 10% FBS were seeded into round-bottomed 96-well microtiter plates to form confluent monolayers during an overnight, 37°C incubation. On the morning of the assay, target cells were washed and then infected with 5 PFU/cell of either wildtype vaccinia virus (vWT), vFIV-gag, or vFIV-env in media composed of equal parts minimum essential medium (MEM) and Leibovitz' L-15, supplemented with L-glutamine and penicillin-streptomycin. Cells were incubated with virus for 1 h, washed once, then incubated in DMEM/L-15 media supplemented with 2% FBS at 37°C for an additional 2 h. Effectors in complete RPMI media without phenol red and supplemented with 5% FBS were added to washed target cells at various effector:target ratios in a final volume of 200 l and allowed to incubate for 4 h at 37°C. Cytotoxicity was measured by release of lactate dehydrogenase (LDH), a stable cytosolic enzyme that is released upon cell lysis, using the CytoTox 96 kit (Promega Biotech), as per manufacturer's instructions.
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